evidence of a conception of compounds falling within the scope
of the count as having utility as COX-2 inhibitors (Exh.
2009).
34. Dr. David B. Reitz, an inventor, testified that
he witnessed the Huang notebook entry (Exh. 2009 and Exh. 2020
at ¶4).
35. Dr. Reitz testified that, on 4 September 1993,
he synthesized a compound said to be 2-[4-(methylthio)phenyl]
benzofuran (Exh. 2020 at ¶5), as a starting material for
synthesizing compounds falling within the scope of the Huang
conception (FF 33), and entered the synthesis procedure in his
notebook (Exh. 2014).
36. Dr. James J. Li testified that he witnessed the
notebook entry of Dr. Reitz on 7 September 1993 (Exh. 2025
at ¶4).
37. Dr. Huang testified that, on 8-9 September 1993,
he synthesized 3-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]
benzofuran (Exh. 2018 at ¶4), a compound falling within the
scope of the count, and entered the synthesis procedure in his
notebook (Exh. 2010). According to Huang, the compound was
assigned the Searle Compound ("SC") identification SC-58394
and is claimed in claim 5 of the '850 application (Exh. 2018
at ¶9 and Paper 46
14
Page: Previous 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next
Last modified: November 3, 2007